<code id='F14F486131'></code><style id='F14F486131'></style>
    • <acronym id='F14F486131'></acronym>
      <center id='F14F486131'><center id='F14F486131'><tfoot id='F14F486131'></tfoot></center><abbr id='F14F486131'><dir id='F14F486131'><tfoot id='F14F486131'></tfoot><noframes id='F14F486131'>

    • <optgroup id='F14F486131'><strike id='F14F486131'><sup id='F14F486131'></sup></strike><code id='F14F486131'></code></optgroup>
        1. <b id='F14F486131'><label id='F14F486131'><select id='F14F486131'><dt id='F14F486131'><span id='F14F486131'></span></dt></select></label></b><u id='F14F486131'></u>
          <i id='F14F486131'><strike id='F14F486131'><tt id='F14F486131'><pre id='F14F486131'></pre></tt></strike></i>

          Home / fashion / fashion

          fashion


          fashion

          author:knowledge    Page View:991
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In